1. Medtech Insight
  2. >>Device Area

Know Labs’ Non-Invasive Blood Glucose Measurement Tech Passes First Test

 
• By Barnaby Pickering

Validation studies show KnowU’s radiofrequency blood-glucose monitor may be able to match the performance of devices from bigger rivals.

Illustration of glucose and red blood cells
Illustration of glucose in blood • Source: Alamy

Know Labs is developing a device that uses radiofrequency waves and artificial intelligence to interrogate and measure blood glucose levels in patients. 

“Each and every molecule/analyte possesses a unique frequency at which it ‘excites’ or ‘resonates,’” Know Labs’ CEO Ron Erickson explained...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

Zimmer Biomet Targets 2027 Launch For Semi-Autonomous Orthopedic Robot After Monogram Acquisition

 
• By Shubham Singh

Zimmer Biomet expects the Monogram deal to meet its financial and strategic criteria, be neutral to adjusted earnings per share from 2025 through 2027 and become accretive thereafter.

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.